AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Mar, 21, 2023
Anavex's A2-73 Blarcamesine's trial result... See more
Mar, 20, 2023
Complete Results!! !
BCRX
Biocryst Pharmaceuticals Inc.
-23.50%
$10.68 - $8.17
Feb 7th 2023 - Mar 21st 2023
Feb, 7, 2023
Long term Bcrx should climb quarter after quarter ... See more
Jan, 12, 2023
Positive news with the early results of the new Fa... See more
Mar, 21, 2023
Anavex's A2-73 Blarcamesine's trial results on 2 previously completed adult phase-3 trials were highly successful.
Mar, 20, 2023
Complete Results!! !
Mar, 16, 2023
But the company actually has never seen before wonderful results.
Feb, 26, 2023
If results hold up, the stock will achieve massive gains.
Feb, 26, 2023
The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.
Feb, 14, 2023
Alzheimer's is the most valuable and most difficult indication and most desired lately.. and only Anavex really has some great results with a great safety record. .
Jan, 24, 2023
The sava results trounce you guys š¤¦š»āāļøš¤¦š»āāļøš¤¦š»āāļøššš
Jan, 24, 2023
Sava has potential and the phase 3 results will show the truth.
Jan, 24, 2023
Sava has good results. .
Mar, 16, 2023
But the company actually has never seen before wonderful results.
Mar, 9, 2023
And, make no mistake, the result are impressive.
Feb, 1, 2023
It is the best results that have been seen in AD.
Jan, 30, 2023
Overall, results impressive.
Jan, 23, 2023
This could be huge in eliminating artificial FUD against the top-line results.
Jan, 13, 2023
$SAVA Market is moving higher as SAVA is expecting data results.
Jan, 9, 2023
Anavex is late like the sun comes up and still produces great results.
Jan, 7, 2023
MOST IMPORTANTLY, THE RESULTS MUST HAVE BEEN GOOD AND PROMISING at each snapshot that leads Remi to use the word "Thrilled" in Dec 6 PR.
Feb, 7, 2023
Long term Bcrx should climb quarter after quarter until they align with projections billion plus!
Jan, 12, 2023
Positive news with the early results of the new Factor D molecule 10013.
Jan, 9, 2023
$BCRX 10% growth quarter over quarter considering flat q1 (as noted with ins payout sched) puts us at 326mil for the year.
Jan, 9, 2023
Relative strength to SPY past 6 weeks, high growth 8 quarters straight.
Jan, 9, 2023
$BCRX 10.5 is the new high for this first quarter.
Jan, 9, 2023
$BCRX so they hit their Q4 numbers, had stellar phase IA results and guided for a 70Mil increase in revenue in 202e.
Jan, 9, 2023
$BCRX sales doubled 4 quarter 70.7 million + 53% year over year..
Jan, 4, 2023
Result - volume up about 36.5% over a normal day.
Dec, 29, 2022
But, with our management, our scientists, and our derisked ORLADEYO keeping the revenues incoming and growing quarter after quarter after quarter.
Dec, 15, 2022
Prem results in q1 and it will beat any drug in the mkt.